All AbMole products are for research use only, cannot be used for human consumption.
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent, potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle blocking, apoptosis, or autophagy in acute myeloid leukemia.
| Molecular Weight | 495.43 |
| Formula | C25H17F4N5O2 |
| CAS Number | 1616428-23-9 |
| Solubility (25°C) | DMSO ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related FLT3 Products |
|---|
| Quizartinib (AC220)
Quizartinib (AC220) is a uniquely potent and selective FLT3 inhibitor. |
| KW-2449
KW-2449 is a novel multitargeted kinase inhibitor of FLT3, ABL and Aurora kinase with IC50 values of 6.6 nM, 14 nM and 48 nM. |
| Tandutinib
Tandutinib (MLN518, CT53518) is an orally active multitargeted tyrosine kinase inhibitor of FLT3 (IC50 = 0.22 μM), and it also inhibits c-Kit and PDGFR with IC50 values of 0.17 μM and 0.20 μM, respectively. Tandutinib has the ability to cross the blood-brain barrier. |
| FF-10101
FF-10101 is a novel irreversible FLT3 inhibitor. |
| TCS 359
TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
